Anti-Obesity Medication Market Share, Size, Trends, Industry Analysis Report, By Mechanism of Action (Centrally Acting Drugs, Peripherally Acting Drugs); By Product; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032

Anti-Obesity Medication Market Share, Size, Trends, Industry Analysis Report, By Mechanism of Action (Centrally Acting Drugs, Peripherally Acting Drugs); By Product; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032



The global anti-obesity medication market size is expected to reach USD 73,470.85 million by 2032, according to a new study by Polaris Market Research. The report “Anti-Obesity Medication Market Share, Size, Trends, Industry Analysis Report, By Mechanism of Action (Centrally Acting Drugs, Peripherally Acting Drugs); By Product; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Anti-obesity medications are pharmaceutical substances crafted to aid individuals in controlling and reducing their surplus body weight, particularly when lifestyle modifications like dietary adjustments and physical activity alone prove insufficient for attaining and sustaining a healthy weight. These medications can operate through diverse mechanisms, such as modifying metabolism, inhibiting fat absorption, and suppressing appetite. Healthcare providers typically prescribe them to patients meeting specific criteria, such as those with elevated body mass index (BMI) or obesity-related health issues like type 2 diabetes.

The market for anti-obesity medication has experienced variable growth over time, influenced by factors such as shifting societal perceptions regarding weight management, the global escalation in obesity rates, and advancements in pharmaceutical research. In recent times, there has been a resurgence of interest in this market, spurred by heightened awareness of the health hazards linked to obesity and the demand for more efficient and safe treatment options. The market has witnessed the introduction of novel medications, including combination therapies, aimed at improving weight loss outcomes and minimizing adverse effects. Furthermore, healthcare providers are increasingly emphasizing a comprehensive approach to managing obesity, encompassing lifestyle modifications, behavioral interventions, and pharmaceutical treatments.

Additionally, with a rising prevalence of obesity worldwide and an increasing awareness of associated health risks, there is a growing demand for effective treatment options. Advancements in drug development technologies present opportunities for the introduction of novel medications with improved efficacy and safety profiles. Additionally, shifting societal attitudes towards weight management and the growing emphasis on preventive healthcare are expected to drive market growth. Moreover, the integration of digital health solutions and personalized medicine approaches offers avenues for tailoring treatments to individual patient needs, thereby expanding market reach. Furthermore, strategic collaborations between pharmaceutical companies and healthcare providers, as well as increased investment in research and development, are poised to unlock further opportunities in this dynamic and evolving market landscape.

Anti-Obesity Medication Market Report Highlights
  • In 2023, the peripherally acting anti-obesity drugs segment accounted for the largest revenue share, due to the mechanism's ability to improve nutrient absorption and reduce feelings of hunger.
  • In 2023, the retail pharmacies segment emerged as the significant revenue share. These outlets provide convenient access to medications for consumers and are commonly located in easily accessible areas within communities.
  • In 2023, the North American region dominated the largest market share due to various factors, such as the high prevalence of obesity and supportive government policies. Additionally, strategic maneuvers like mergers, acquisitions, and partnerships among pharmaceutical giants play a pivotal role in shaping the competitive landscape.
  • The global key market players include Boehringer Ingelheim International GmbH, Currax Pharmaceuticals, Gelesis, GlaxoSmithKline plc, Kintai Therapeutics, Novartis AG, Novo Nordisk A/S, Rhythm Pharmaceuticals, Inc., VIVUS LLC.
Polaris Market Research has segmented the Anti-Obesity Medication market report based on mechanism of action, product, distribution channel, and region:

Anti-Obesity Medication, Mechanism of Action Outlook (Revenue - USD Million, 2019 - 2032)
  • Centrally Acting Drugs
  • Peripherally Acting Drugs
Anti-Obesity Medication, Product Outlook (Revenue - USD Million, 2019 - 2032)
  • Off Label
- Semaglutide (Wegovy)

- Topiramate (Xenical Alli)

- Dulaglutide (Trulicity)

- Liraglutide (Semaglutide (Wegovy))

- Others
  • Approved
- Liraglutide (Orlistat)

- Bupropion-naltrexone (Contrave)

- Orlistat
  • Alli
  • Xenical
- Setmelanotide (Imcivree)

- Tirzepatide (Zepbound)

- Phentermine-topiramate (Qsymia)

- Semaglutide (Wegovy

Anti-Obesity Medication, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
Anti-Obesity Medication, Regional Outlook (Revenue - USD Million, 2019 - 2032)
  • North America
- U.S.

- Canada
  • Europe
- Germany

- UK

- France

- Italy

- Spain

- Russia

- Netherlands

- Rest of Europe
  • Asia Pacific
- China

- India

- Japan

- South Korea

- Indonesia

- Malaysia

- Australia

- Rest of Asia Pacific
  • Latin America
- Argentina

- Brazil

- Mexico

- Rest of Latin America
  • Middle East & Africa
- UAE

- Saudi Arabia

- Israel

- South Africa

- Rest of Middle East & Africa


1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Global Anti-Obesity Medication Market Insights
4.1. Anti-Obesity Medication Market – Distribution Channel Snapshot
4.2. Anti-Obesity Medication Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. The increasing incidence of obesity
4.2.1.2. A rise in the occurrence of childhood obesity and morbid obesity
4.2.2. Restraints and Challenges
4.2.2.1. Lack of long-term effectiveness data
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Anti-Obesity Medication Market Distribution Channel Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis
5. Global Anti-Obesity Medication Market, by Product
5.1. Key Findings
5.2. Introduction
5.2.1. Global Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
5.3. Off Label
5.3.1. Global Anti-Obesity Medication Market, by Off Label, by Region, 2019-2032 (USD Million)
5.3.2. Semaglutide (Wegovy)
5.3.2.1. Global Anti-Obesity Medication Market, by Semaglutide (Wegovy), by Region, 2019-2032 (USD Million)
5.3.3. Topiramate (Xenical Alli)
5.3.3.1. Global Anti-Obesity Medication Market, by Topiramate (Xenical Alli), by Region, 2019-2032 (USD Million)
5.3.4. Dulaglutide (Trulicity)
5.3.4.1. Global Anti-Obesity Medication Market, by Dulaglutide (Trulicity), by Region, 2019-2032 (USD Million)
5.3.5. Liraglutide (Semaglutide (Wegovy))
5.3.5.1. Global Anti-Obesity Medication Market, by Liraglutide (Semaglutide (Wegovy)), by Region, 2019-2032 (USD Million)
5.3.6. Others
5.3.6.1. Global Anti-Obesity Medication Market, by Others, by Region, 2019-2032 (USD Million)
5.4. Approved
5.4.1. Global Anti-Obesity Medication Market, by Approved, by Region, 2019-2032 (USD Million)
5.4.2. Liraglutide (Orlistat)
5.4.2.1. Global Anti-Obesity Medication Market, by Liraglutide (Orlistat), by Region, 2019-2032 (USD Million)
5.4.3. Bupropion-naltrexone (Contrave)
5.4.3.1. Global Anti-Obesity Medication Market, by Bupropion-naltrexone (Contrave), by Region, 2019-2032 (USD Million)
5.4.4. Orlistat
5.4.4.1. Global Anti-Obesity Medication Market, by Orlistat, by Region, 2019-2032 (USD Million)
5.4.4.2. Alli
5.4.4.2.1. Global Anti-Obesity Medication Market, by Alli, by Region, 2019-2032 (USD Million)
5.4.4.3. Xenical
5.4.4.3.1. Global Anti-Obesity Medication Market, by Xenical, by Region, 2019-2032 (USD Million)
5.4.5. Setmelanotide (Imcivree)
5.4.5.1. Global Anti-Obesity Medication Market, by Setmelanotide (Imcivree), by Region, 2019-2032 (USD Million)
5.4.6. Tirzepatide (Zepbound)
5.4.6.1. Global Anti-Obesity Medication Market, by Tirzepatide (Zepbound), by Region, 2019-2032 (USD Million)
5.4.7. Phentermine-topiramate (Qsymia)
5.4.7.1. Global Anti-Obesity Medication Market, by Phentermine-topiramate (Qsymia), by Region, 2019-2032 (USD Million)
5.4.8. Semaglutide (Wegovy)
5.4.8.1. Global Anti-Obesity Medication Market, by Semaglutide (Wegovy), by Region, 2019-2032 (USD Million)
6. Global Anti-Obesity Medication Market, by Mechanism of Action
6.1. Key Findings
6.2. Introduction
6.2.1. Global Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
6.3. Centrally Acting Drugs
6.3.1. Global Anti-Obesity Medication Market, by Centrally Acting Drugs, by Region, 2019-2032 (USD Million)
6.4. Peripherally Acting Drugs
6.4.1. Global Anti-Obesity Medication Market, by Peripherally Acting Drugs, by Region, 2019-2032 (USD Million)
7. Global Anti-Obesity Medication Market, by Distribution Channel
7.1. Key Findings
7.2. Introduction
7.2.1. Global Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
7.3. Hospital Pharmacies
7.3.1. Global Anti-Obesity Medication Market, by Hospital Pharmacies, By Region, 2019-2032 (USD Million)
7.4. Retail Pharmacies
7.4.1. Global Anti-Obesity Medication Market, by Retail Pharmacies, By Region, 2019-2032 (USD Million)
7.5. Others
7.5.1. Global Anti-Obesity Medication Market, by Others, By Region, 2019-2032 (USD Million)
8. Global Anti-Obesity Medication Market, by Geography
8.1. Key findings
8.2. Introduction
8.2.1. Anti-Obesity Medication Market Assessment, By Geography, 2019-2032 (USD Million)
8.3. Anti-Obesity Medication Market – North America
8.3.1. North America: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.3.2. North America: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.3.3. North America: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.3.4. Anti-Obesity Medication Market – U.S.
8.3.4.1. U.S.: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.3.4.2. U.S.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.3.4.3. U.S.: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.3.5. Anti-Obesity Medication Market – Canada
8.3.5.1. Canada: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.3.5.2. Canada.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.3.5.3. Canada: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.4. Anti-Obesity Medication Market – Europe
8.4.1. Europe: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.4.2. Europe.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.4.3. Europe: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.4.4. Anti-Obesity Medication Market – UK
8.4.4.1. UK: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.4.4.2. UK.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.4.4.3. UK: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.4.5. Anti-Obesity Medication Market – France
8.4.5.1. France: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.4.5.2. France.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.4.5.3. France: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.4.6. Anti-Obesity Medication Market – Germany
8.4.6.1. Germany: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.4.6.2. Germany.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.4.6.3. Germany: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.4.7. Anti-Obesity Medication Market – Italy
8.4.7.1. Italy: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.4.7.2. Italy.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.4.7.3. Italy: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.4.8. Anti-Obesity Medication Market – Spain
8.4.8.1. Spain: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.4.8.2. Spain.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.4.8.3. Spain: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.4.9. Anti-Obesity Medication Market – Netherlands
8.4.9.1. Netherlands: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.4.9.2. Netherlands.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.4.9.3. Netherlands: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.4.10. Anti-Obesity Medication Market – Russia
8.4.10.1. Russia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.4.10.2. Russia.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.4.10.3. Russia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.5. Anti-Obesity Medication Market – Asia Pacific
8.5.1. Asia Pacific: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.5.2. Asia Pacific.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.5.3. Asia Pacific: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.5.4. Anti-Obesity Medication Market – China
8.5.4.1. China: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.5.4.2. China.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.5.4.3. China: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.5.5. Anti-Obesity Medication Market – India
8.5.5.1. India: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.5.5.2. India.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.5.5.3. India: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.5.6. Anti-Obesity Medication Market – Malaysia
8.5.6.1. Malaysia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.5.6.2. Malaysia.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.5.6.3. Malaysia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.5.7. Anti-Obesity Medication Market – Japan
8.5.7.1. Japan: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.5.7.2. Japan.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.5.7.3. Japan: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.5.8. Anti-Obesity Medication Market – Indonesia
8.5.8.1. Indonesia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.5.8.2. Indonesia.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.5.8.3. Indonesia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.5.9. Anti-Obesity Medication Market – South Korea
8.5.9.1. South Korea: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.5.9.2. South Korea.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.5.9.3. South Korea: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.6. Anti-Obesity Medication Market – Middle East & Africa
8.6.1. Middle East & Africa: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.6.2. Middle East & Africa.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.6.3. Middle East & Africa: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.6.4. Anti-Obesity Medication Market – Saudi Arabia
8.6.4.1. Saudi Arabia: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.6.4.2. Saudi Arabia.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.6.4.3. Saudi Arabia: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.6.5. Anti-Obesity Medication Market – UAE
8.6.5.1. UAE: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.6.5.2. UAE.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.6.5.3. UAE: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.6.6. Anti-Obesity Medication Market – Israel
8.6.6.1. Israel: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.6.6.2. Israel.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.6.6.3. Israel: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.6.7. Anti-Obesity Medication Market – South Africa
8.6.7.1. South Africa: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.6.7.2. South Africa.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.6.7.3. South Africa: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.7. Anti-Obesity Medication Market – Latin America
8.7.1. Latin America: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.7.2. Latin America.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.7.3. Latin America: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.7.4. Anti-Obesity Medication Market – Mexico
8.7.4.1. Mexico: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.7.4.2. Mexico.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.7.4.3. Mexico: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.7.5. Anti-Obesity Medication Market – Brazil
8.7.5.1. Brazil: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.7.5.2. Brazil.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.7.5.3. Brazil: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
8.7.6. Anti-Obesity Medication Market – Argentina
8.7.6.1. Argentina: Anti-Obesity Medication Market, by Product, 2019-2032 (USD Million)
8.7.6.2. Argentina.: Anti-Obesity Medication Market, by Distribution Channel, 2019-2032 (USD Million)
8.7.6.3. Argentina: Anti-Obesity Medication Market, by Mechanism of Action, 2019-2032 (USD Million)
9. Competitive Landscape
9.1. Expansion and Acquisition Analysis
9.1.1. Expansion
9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions
10. Company Profiles
10.1. Boehringer Ingelheim International GmbH
10.1.1. Company Overview
10.1.2. Financial Performance
10.1.3. Product Benchmarking
10.1.4. Recent Development
10.2. Currax Pharmaceuticals
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. Product Benchmarking
10.2.4. Recent Development
10.3. Gelesis
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. Product Benchmarking
10.3.4. Recent Development
10.4. GlaxoSmithKline plc
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. Product Benchmarking
10.4.4. Recent Development
10.5. Kintai Therapeutics
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. Product Benchmarking
10.5.4. Recent Development
10.6. Novartis AG
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. Product Benchmarking
10.6.4. Recent Development
10.7. Novo Nordisk A/S
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. Product Benchmarking
10.7.4. Recent Development
10.8. Rhythm Pharmaceuticals, Inc
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. Product Benchmarking
10.8.4. Recent Development
10.9. VIVUS LLC
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. Product Benchmarking
10.9.4. Recent Development

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings